BioCentury | Apr 15, 2013
Company News

T Cell Sciences, Novartis Pharma AG deal

...Novartis obtained options to license TCEL's TP10 soluble complement receptor 1 (SCR-1) and the gene for...
...two-year agreement, Novartis could license TP10 exclusively for transplant with worldwide marketing rights, except Japan. TCEL...
...option fees and supplies of TP10 from Novartis for development in other indications, a combination TCEL...
BioCentury | Apr 15, 2013
Company News

T Cell Sciences board of directors update

...T Cell Sciences Inc. (TCEL), Needham, Mass. Business: Autoimmune/Inflammation Retired: James Grant as chairman; also John...
BioCentury | Apr 15, 2013
Company News

T Cell Sciences board of directors update

...T Cell Sciences Inc. (TCEL), Needham, Mass. Business: Autoimmune/Inflammation, Diagnostics/Imaging Appointed: Harry Penner; currently president and...
BioCentury | Aug 24, 1998
Company News

T Cell Sciences, Virus Research deal

...begin trading on NASDAQ on Aug. 24 under the symbol AVAN. T Cell Sciences Inc. (TCEL...
BioCentury | Aug 17, 1998
Finance

New frontier: Animal health

...B8) . . . Virus Research Institute (VRII), which is merging with T Cell Sciences (TCEL...
...announcing results of a Phase II study of its rotavirus vaccine for infants (see B8). TCEL...
BioCentury | Aug 3, 1998
Finance

Drought relief

...a 1997 settlement of a lawsuit involving TCEL's office lease (see BioCentury, Sept. 2, 1997). TCEL...
...a 1997 settlement of a lawsuit involving TCEL's office lease (see BioCentury, Sept. 2, 1997). TCEL...
BioCentury | Jul 20, 1998
Clinical News

T Cell Sciences regulatory update

...soluble form of complement receptor 1 used to minimize complement-mediated injury. T Cell Sciences Inc. (TCEL...
BioCentury | Jul 13, 1998
Company News

T Cell Sciences management update

...T Cell Sciences Inc. (TCEL), Needham, Mass. Business: Autoimmune/Inflammation, Cardiovascular Hired: Thomas Fuerst as VP of...
BioCentury | May 26, 1998
Clinical News

T Cell Sciences regulatory update

...measure the amount of a cell-associated molecule present in the samples. T Cell Sciences Inc. (TCEL...
BioCentury | May 18, 1998
Strategy

Some questions left unresolved

...said Una Ryan, TCEL's president and CEO who will retain the same titles at Avant. TCEL...
...Friday at $4.031, up $0.719, has a market cap of about $36 million. Ryan said TCEL...
...partners for TCEL's CETP technology and VRII's Therapore immunotherapy delivery system. To conclude the deal, TCEL...
Items per page:
1 - 10 of 75